SWOT Analysis for Mankind Pharma Ltd.

Benjamin Graham Value Screen
Strong Momentum: Price above short, medium and long term moving averages
Expensive Rockets (DVM)
Relative Outperformance versus Industry over 1 Month
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Increasing profits every quarter for the past 2 quarters
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
RSI indicating price strength
Top Gainers
Stocks Outperforming their Industry Price Change in the Quarter

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

RSI indicating price strength

Top Gainers

Stocks Outperforming their Industry Price Change in the Quarter

Promoter decreasing their shareholding
PE higher than Industry PE
High PE (PE > 40)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Declining Net Cash Flow : Companies not able to generate net cash
Declining profitability: Falling ROCE

Promoter decreasing their shareholding

PE higher than Industry PE

High PE (PE > 40)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Declining Net Cash Flow : Companies not able to generate net cash

Declining profitability: Falling ROCE

Broker price or reco upgrades in last month
Brokers upgraded recommendation or target price in the past three months
Broker Upgrades: Stocks where brokers upgraded recommendation or price target in the past one month
FII / FPI or Institutions increasing their shareholding
Broker price or reco upgrades in last month
Mutual Funds Increased Shareholding over the Past Two Months

Broker price or reco upgrades in last month

Brokers upgraded recommendation or target price in the past three months

Broker Upgrades: Stocks where brokers upgraded recommendation or price target in the past one month

FII / FPI or Institutions increasing their shareholding

Broker price or reco upgrades in last month

Mutual Funds Increased Shareholding over the Past Two Months

Companies with high market cap, lower public shareholding
MFs decreased their shareholding last quarter

Companies with high market cap, lower public shareholding

MFs decreased their shareholding last quarter

Rising Delivery Percentage Compared to Prev Day
Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes
Bullish or Bearish Candlestick Strength - Indices
Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Rising Delivery Percentage Compared to Prev Day

Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes

Bullish or Bearish Candlestick Strength - Indices

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks

Mankind Pharma Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

Mankind Pharma Ltd. has 16 Strengths, 6 Weaknesses, 6 Opportunities and 2 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Benjamin Graham Value Screen

Strong Momentum: Price above short, medium and long term moving averages

Expensive Rockets (DVM)

Relative Outperformance versus Industry over 1 Month

PEG lower than Industry PEG

High Momentum Scores (Technical Scores greater than 50)

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Increasing profits every quarter for the past 2 quarters

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

RSI indicating price strength

Top Gainers

Stocks Outperforming their Industry Price Change in the Quarter

Promoter decreasing their shareholding

PE higher than Industry PE

High PE (PE > 40)

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Declining Net Cash Flow : Companies not able to generate net cash

Declining profitability: Falling ROCE

Broker price or reco upgrades in last month

Brokers upgraded recommendation or target price in the past three months

Broker Upgrades: Stocks where brokers upgraded recommendation or price target in the past one month

FII / FPI or Institutions increasing their shareholding

Broker price or reco upgrades in last month

Mutual Funds Increased Shareholding over the Past Two Months

Companies with high market cap, lower public shareholding

MFs decreased their shareholding last quarter

Rising Delivery Percentage Compared to Prev Day

Rising Delivery Percentage Compared to Previous Day and Month, Strong Volumes

Bullish or Bearish Candlestick Strength - Indices

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks